Erica Mayer
Dana-Farber Cancer Institute · Dana Farber Cancer Institute, Inc.
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Erica Mayer as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 17:22 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06001762 · TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast CancerDana-Farber Cancer Institute · active not recruiting · Breast Cancer, Early-stage Breast Cancer, High Risk Breast Carcinoma · principal investigator
- Ph3NCT02513394 · PALbociclib CoLlaborative Adjuvant StudyAlliance Foundation Trials, LLC. · active not recruiting · Breast Cancer · principal investigator
- Ph2NCT02040857 · Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast CancerDana-Farber Cancer Institute · completed · Breast Cancer · principal investigator
- Ph2NCT01982448 · Cisplatin vs Paclitaxel for Triple Negative Breast CancerDana-Farber Cancer Institute · completed · Triple Negative Breast Cancer · principal investigator
- Ph2NCT01827787 · Eribulin in HER2 Negative Metastatic BrCaDana-Farber Cancer Institute · completed · Breast Cancer · principal investigator
- Ph2NCT00925652 · Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast CancerDana-Farber Cancer Institute · terminated · Breast Cancer · study chair
- Ph1NCT00717340 · A Phase 1b/2a, Open-Label, Multi-Center Study of Tivozanib (AV-951) in Combination With Paclitaxel in Subjects With Advanced or Metastatic Breast CancerAVEO Pharmaceuticals, Inc. · completed · Metastatic Breast Cancer · principal investigator
- N/ANCT00674011 · Hypertension in Breast Cancer Patients Receiving BevacizumabDana-Farber Cancer Institute · terminated · Breast Cancer · principal investigator
- Ph1NCT00496665 · ZD6474 (Zactima) and Metronomic Chemotherapy in Advanced Breast CancerDana-Farber Cancer Institute · completed · Metastatic Breast Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 17:22 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Clinical Trials CoreP50CA168504 · NCI · DANA-FARBER CANCER INST · fiscal years 2013 to 2017 · $406,769 awarded in 2017Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 17:22 UTC. The ranking covers the 200 most relevant of 154 PubMed records, and a shared surname and initials can bring in a namesake. All 154 on PubMed
- 1,071 citationsRCR 37.1
- Altered rectal perception is a biological marker of patients with irritable bowel syndrome.Gastroenterology · 1995817 citationsRCR 28.3
- Consumption of fermented milk product with probiotic modulates brain activity.Gastroenterology · 2013780 citationsRCR 27.7
- 434 citationsRCR 12.6
- TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer.J Clin Oncol · 2012419 citationsRCR 10.3
- TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.J Clin Oncol · 2015335 citationsRCR 9.5
- Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist.Aliment Pharmacol Ther · 1999312 citationsRCR 10.7
- Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2).Eur Respir J · 2015257 citationsRCR 10.4
- A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome.Arch Intern Med · 2001244 citationsRCR 7.8
- Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.Lancet Oncol · 2019218 citationsRCR 7.4